Weekly Irinotecan and Concurrent Radiation Therapy for Stage III Unresectable NSCLC
July 2nd 2000In preclinical studies, the topoisomerase I inhibitor irinotecan (Camptosar, CPT-11) has demonstrated activity as a radiosensitizer, probably due to its ability to inhibit potentially lethal radiation damage repair. We conducted a